Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2018 | Novel therapies on the horizon for cutaneous T-cell lymphoma

Rudolf Stadler • 27 Sep 2018
EORTC CLTF 2018
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases T-Cell Lymphoma Antibodies Brentuximab vedotin Mogamulizumab

Speaking from the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, Rudolf Stadler, MD, PhD, of the University Medical Center Minden, Minden, Germany, discusses new therapy options for cutaneous T-cell lymphoma, including brentuximab vedotin and mogamulizumab. In addition, Prof. Stadler discusses promising targets for therapeutic antibodies.

More from Rudolf Stadler

1:25
PARCT: atezolizumab for CTCL and next steps
Rudolf Stadler • 15 Oct 2021
1:23
RESMAIN: HDAC inhibitor resminostat for CTCL
Rudolf Stadler • 15 Oct 2021
1:27
Lacutamab for CTCL
Rudolf Stadler • 15 Oct 2021
1:15
Advances in understanding the molecular pathogenesis of CTCL
Rudolf Stadler • 15 Oct 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals